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SUMMARY
N-Myristoyltransferase (NMT) modulates protein
function through the attachment of the lipidmyristate
to the N terminus of target proteins, and is a prom-
ising drug target in eukaryotic parasites such as
Leishmania donovani. Only a small number of NMT
substrates have been characterized in Leishmania,
and a global picture of N-myristoylation is lacking.
Here, we use metabolic tagging with an alkyne-func-
tionalized myristic acid mimetic in live parasites fol-
lowed by downstream click chemistry and analysis
to identify lipidated proteins in both the promastigote
(extracellular) and amastigote (intracellular) life
stages. Quantitative chemical proteomics is used to
profile target engagement by NMT inhibitors, and to
define the complement of N-myristoylated proteins.
Our results provide new insight into the multiple
pathways modulated by NMT and the pleiotropic ef-
fects of NMT inhibition. This work constitutes the first
global experimental analysis of protein lipidation in
Leishmania, and reveals the extent of NMT-related
biology yet to be explored for this neglected human
pathogen.
INTRODUCTION
Over 300 million people are at risk from the leishmaniases, a
spectrum of neglected tropical parasitic diseases strongly asso-
ciated with poverty, which cause around 30,000 deaths annually
(Alvar et al., 2012). The diseases take twomain forms: cutaneous
leishmaniasis (CL), manifesting as skin lesions, and visceral
leishmaniasis (VL), also known as kala-azar, a systemic infection
causing swelling of organs, fever, and anemia, that is almost
invariably fatal if left untreated. The causative agents of these
debilitating diseases are species of the Leishmania protozoan
parasite, a unicellular eukaryote. Leishmania donovani (Ld) is
the principle causative agent of VL while Leishmania major
(Lm) is themain species responsible for CL. The parasite is trans-
mitted by sand fly vectors, which inoculate the promastigote
forms into the human host. Here, they are taken up by phago-
cytic cells, mainly macrophages, and transform into the obligate
intracellular amastigotes, which then replicate and can infect
other phagocytes. Transmission occurs when a sand fly takes
up infected cells in a blood meal. Inside the sand fly midgut,
amastigotes transform into promastigotes. There are currently
few drugs to treat the leishmaniases, and those that are available
have problems of toxicity, teratogenicity, high cost, difficult
administration, and/or parasite resistance. These drugs work
via nonspecific antibiotic effects, such as disruption of cell mem-
branes, or their mode of action is unknown (Tate et al., 2014).
Novel drugs with a defined mechanism of action, high efficacy
and low toxicity are urgently required to combat these devas-
tating diseases.
The enzyme myristoyl-CoA:protein N-myristoyltransferase
(NMT) has recently been validated as a promising drug target in
trypanosomiasis (Frearson et al., 2010) and malaria (Wright
et al., 2014), diseases caused by the protozoan parasites Trypa-
nosoma brucei and species of Plasmodium, respectively. NMT
has also been proposed as a potential drug target for infections
caused by parasitic nematodes (Galvin et al., 2014) and for the
leishmaniases (Price et al., 2003). NMT catalyzes a protein modi-
fication, the attachment of theC14:0 lipidmyristate (Myr, tetrade-
canoic acid, Figure 1A) to the N-terminal glycine residue of
specific target proteins in the cell. This reaction usually occurs
cotranslationally during ribosomal synthesis of the protein,
affording a stable, amide-linked lipid thatmodulatesprotein func-
tion, typically promoting protein localization to cellular mem-
branes (Wright et al., 2010). NMT has been characterized in Ld
and Lm and appears to be essential for survival of promastigotes
in both organisms (Brannigan et al., 2010; Price et al., 2003),
although evidence for the importance of NMT in amastigotes
has yet to be reported. Structure-based design and high-
throughput screening has led to the discovery of several distinct
NMT inhibitor series (Bell et al., 2012; Brannigan et al., 2014;
Hutton et al., 2014; Olaleye et al., 2014). Around 60 Leishmania
proteins have been predicted to be N-myristoylated using
bioinformatic approaches based on learning sets from unrelated
organisms (Mills et al., 2007), but experimental evidence has only
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been reported for six; these include ADP-ribosylation factor-like
protein LdARL1 (Sahin et al., 2008), LdARL3A (Cuvillier et al.,
2000), and several proteins that have been shown to carry a
dual N-myristoylation and S-palmitoylation acylation motif. This
latter modification involves the incorporation of hexadecanoic
acid or other long chain fatty acids via a thioester linkage at a
cysteine side chain, sometimes near the N terminus close to an
N-myristoylation site. An example is dually acylated protein
HASPB, amember of a family of hydrophilic acylated surfacepro-
teins important for parasite development in the insect vector
(Sadlova et al., 2010). HASPB is unusual for an N-myristoylated
protein in being localized to the outer leaflet of the plasma mem-
brane in infective stages (Dennyet al., 2000;Macleanet al., 2012).
Similarly, SMP-1, one of several small myristoylated proteins, is
flagellum-targeted by acylation (Tull et al., 2004). The SMPs are
targeted to different subcellular compartments depending on
N-terminal acylation and other sequencemotifs (Tull et al., 2012).
Global profiling of protein lipidation in living cells by standard
biochemical methods is challenging. We and others have
made use of bioorthogonal labeling chemistries such as the cop-
per-catalyzed cycloaddition of an alkyne and azide (CuAAC) to
capture proteins metabolically tagged with alkyne or azide fatty
B C D
or
A
YnMyr
Myristic acid
Metabolic 
tagging
CuAAC
m/z
proteomics
gel 
analysis
E
Sample
-
C
/M
N
aO
H
Fluorescence
Pronase - +
YnMyr - + - +
CuAAC
reagent Az Az Yn Yn Az
Metabolic
tagging
P
al
YnP
al
M
yr
A
zM
yr
YnM
yr
Fluorescence
CB CB
CB
250 -
100 -
75 -
50 -
37 -
25 -
20 -
15 -
250 -
150 -
100 -
75 -
50 -
37 -
25 -
20 -
Fluorescence
250 -
100 -
75 -
50 -
37 -
25 -
20 -
15 -
10 -
biotin
TAMRA
Figure 1. Tagging of Proteins by YnMyr in Leishmania
(A) Overview of metabolic tagging of proteins with myristic acid analog YnMyr and analysis following CuAAC labeling.
(B) YnMyr tagging in L. donovani promastigotes. Following CuAAC labeling with reagent AzTB, samples were precipitated with CHCl3/MeOH (CM) or with MeOH
and then treated with NaOH as indicated. CB, Coomassie blue.
(C) The effect of pronase digestion on tagging. Pronase digests protein resulting in a loss of the discrete fluorescent bands but leaving the diffuse labeling
relatively unaffected.
(D) YnMyr tagging compared with other analogs YnPal and AzMyr in promastigotes. Pal, palmitic acid; Myr, myristic acid. CuAAC capture reagent: Az, AzTB;
Yn, YnTB.
(E) Chemical tools. Additional labeling data are shown in Figure S1.
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acids (Grammel and Hang, 2013). In this approach, fatty acid an-
alogs bearing the biologically inert azide or alkyne functional
group are incubated with cells in culture and incorporated by
cellular machinery into lipidated proteins. Following cell lysis,
proteins can be functionalized via CuAAC with useful groups
such as a fluorophore for visualization by in-gel fluorescence
and a biotin affinity handle for enrichment, enabling subsequent
mass spectrometry analysis and identification of modified pro-
teins. Here, we use an alkyne-tagged myristate analog, YnMyr
(tetradecynoic acid, Figure 1A), which has been previously
used as a mimic for myristic acid in several systems, including
mammalian cells (Thinon et al., 2014) and Plasmodium falcipa-
rum (Wright et al., 2014), to profile the lipidome of L. donovani.
We further combine this chemical proteomic tool with small
molecule NMT inhibitors to confirm target engagement inside
live parasites, and to define the complement of NMT substrates.
RESULTS
YnMyr Tags Proteins in L. donovani
We first sought to demonstrate that YnMyr can tag proteins in
Leishmania, since this has not previously been reported. Meta-
bolic tagging of Ld promastigotes with 50 mM YnMyr followed
by CuAAC with biotin and fluorophore-functionalized reagent
AzTB (Figures 1 and S1) gave several distinct fluorescent bands,
and a diffuse smear between 18–30 kDa (Figure 1B). This diffuse
labeling was effectively removed by CHCl3/MeOH precipitation
or treatment with strong base and was resistant to pronase
digestion (Figures 1B and 1C), suggesting YnMyr incorporation
into a nonprotein component. Leishmania species synthesize
complex glycolipid macromolecules, including glycosylphos-
phatidylinositol (GPI)-anchored proteins, glycoinositol phos-
pholipids (GIPLs), and the complex glycoconjugate lipophos-
phoglycan (LPG) (Ferguson, 1997). Since these molecules
contain acyl-fatty acids or ether-linked alkyl chains, YnMyr incor-
poration into such molecules is not unexpected; indeed, myris-
tate is known to be incorporated into GIPLs and the GPI anchors
of some proteins (Etges et al., 1986; Ralton et al., 2002). In addi-
tion to removal of the diffuse band, treatment with base in pro-
mastigotes resulted in loss of several other bands (Figure 1B).
A well-studied protein in Leishmania is the surface protease
GP63, which incorporates myristic acid into its GPI anchor
(Etges et al., 1986). Consistent with this, GP63 could be detected
after pull-down of YnMyr tagged promastigote lysate onto strep-
tavidin beads (Figure S1). Hydroxylamine treatment of lysates
gave a slight reduction in signal intensity of several weak bands,
suggesting that YnMyr may also be incorporated into some
S-acylation sites (Figure S1).
Labeling in promastigotes was time dependent, outcompeted
by myristic acid and inhibited in the presence of the protein syn-
thesis inhibitor cycloheximide (Figure S1), showing that YnMyr
incorporation is dependent on de novo protein synthesis. Inter-
estingly, although azido-myristate AzMyr produced a similar,
but not identical, labeling pattern, this analog did not label the
diffuse bands (Figure 1D), suggesting that the biosynthetic path-
ways incorporating the analog into these molecules may be less
tolerant to modifications in the lipid structure. The background
labeling generated by CuAAC with YnTB, the alkyne version of
the AzTB capture reagent, was also higher (Figure 1D), as has
been noted previously by others (Charron et al., 2009). These
data suggest that YnMyr is the more suitable probe for labeling
in Leishmania. Longer chain palmitic acid analog YnPal showed
a distinct labeling pattern to the myristate analogs (Figure 1D),
indicating that fatty acyl chain length is important for protein lip-
idation in these cells.
Metabolic tagging with YnMyr in the amastigote stage gave a
distinct labeling pattern compared with promastigotes and no
diffuse bands (Figure 2A). While GIPLs are expressed in both
life cycle stages, LPG andGPI-anchored proteins are downregu-
lated in the amastigote stage (McConville and Blackwell, 1991),
suggesting that the diffuse labeling observed in promastigotes is
related to specific glycolipid biosynthetic pathways. Known
N-myristoylated protein HASPB (Alce et al., 1999) could be de-
tected by western blot after pull-down of tagged proteins onto
streptavidin beads in both life stages (Figure 2A), although the
overall incorporation of YnMyr into HASPB was low, as may be
expected given that the tagged analog competes for substrates
with endogenous lipid. To confirm the nature of HASPB labeling,
YnMyr tagging was performed in L. major strains expressing a
fusion protein consisting of GFP fused to either the N-terminal
18 residues of HASPB (wild-type [WT] 18AA-HASPB-GFP), or
to a mutant in which the N-terminal glycine was mutated to
alanine (G2A) (Denny et al., 2000). The global labeling pattern
was similar between these strains and comparable with that in
L. donovani (Figure S1). Following enrichment of YnMyr tagged
proteins, GFP was detected in the WT sample but not in the
G2A mutant, consistent with canonical attachment of YnMyr to
the N-terminal glycine by NMT; endogenous HASPB was en-
riched from both WT and G2A mutants (Figure 2B).
The freshly harvested ex vivo amastigotes used in the current
study are a practical model system for studying the host infective
stage of Leishmania, but methods to study this intracellular para-
site in its native environment inside mammalian macrophages
would be particularly useful for future host-parasite studies. To
establish whether YnMyr can penetrate the amastigote inside
the parasitophorous vacuole, macrophages infected with Ld
amastigotes were incubated with YnMyr for 18 hr, lysed, and
samples analyzed by gel; uninfected macrophages were used
as a control. Strong labeling of macrophage proteins dominated
in-gel fluorescence of both infected and uninfected samples, as
might be expected from the low multiplicity of infection (10) of
this intracellular model (Figure 2C). HASPB was immunoprecip-
itated (IP) from lysates and incubated with CuAAC reagents on-
bead, followed by protein elution and analysis by western blot.
HASPB was present only in infected samples, as expected,
and a fluorescent band was also visible specifically in YnMyr
tagged samples at the same molecular weight (Figure 2D). This
IP-click approach, which also allows for detection of tagged
HASPB in ex vivo amastigote samples (Figure 2E), circumvents
the challenges posed by the relatively low abundance of parasite
relative to host cell material. These data show that YnMyr also
tags the N-myristoylated protein HASPB in the context of Leish-
mania-infected macrophages.
Global Proteomic Identification of YnMyr Tagged
Proteins in Promastigotes and Amastigotes
Validating the tagging of specific proteins by western blot, as
shown above for HASPB, is a low-throughput method and
Chemistry & Biology 22, 1–13, March 19, 2015 ª2015 The Authors 3
Please cite this article in press as: Wright et al., Global Analysis of Protein N-Myristoylation and Exploration of N-Myristoyltransferase as a Drug Target
in the Neglected Human Pathogen Leishmania donovani, Chemistry & Biology (2015), http://dx.doi.org/10.1016/j.chembiol.2015.01.003
dependent on the availability of an antibody for the protein of in-
terest. To carry out the global identification of YnMyr tagged pro-
teins, Neutravidin-enriched proteins were digested on-bead with
trypsin and peptides analyzed via liquid chromatography-tan-
dem mass spectrometry (LC-MS/MS). For the MS experiments,
a capture reagent (AzRB, Supplemental Experimental Proce-
dures) containing a trypsin-cleavable motif between the azide
and biotin groups was designed and used. We have previously
used similar reagents to facilitate release of YnMyr-modified
peptides from Neutravidin beads for identification (Thinon
et al., 2014). A label-free quantification (LFQ) approach (Cox
et al., 2014) was used to assess enrichment over myristic acid
controls. The nature of an enrichment experiment means that
hits are often not detected in controls, and analysis of the data
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Figure 2. YnMyr Tags Known N-Myristoylated Protein HASPB
(A) HASPB is labeled in promastigotes and amastigotes. Parasites were tagged with myristic acid or YnMyr, proteins labeled via CuAAC with AzTB, and a portion
enriched by pull-down (PD) onto streptavidin beads. Four-fold more sample loaded after PD compared with before. Western blot (WB) revealed that HASPB is
specifically enriched in the YnMyr samples.
(B) HASPB is labeled on the N-terminal glycine. L.major parasites expressing the HASPBN terminus (18 residues;WT) fused toGFP or a G2Amutant were tagged
with YnMyr and processed as above. Top: WB for GFP shows that only theWT protein and not the G2Amutant is tagged. Bottom: endogenous HASPB is tagged
in both samples.
(C) In-gel fluorescence analysis of YnMyr tagged proteins from macrophages infected with L. donovani or cultured alone.
(D) HASPB is tagged in intracellular amastigotes. HASPBwas immunoprecipitated (IP) from lysates derived from infected or uninfectedmacrophages taggedwith
YnMyr, and beads incubated with CuAAC reagents. In-gel fluorescence (top) shows a YnMyr- and infection-specific band at the expected migration for HASPB
(arrow). WB (bottom) shows that HASPB (arrow) is present only in infected samples. * indicates antibody IgG heavy chain.
(E) HASPB IP and CuAAC using ex vivo amastigotes.
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was approached in twoways. First, values for missing LFQ inten-
sities were imputed from a normal distribution to simulate values
at the lower limit of detection and a permutation-corrected (false
discovery rate, FDR) t test was applied to define significance
(Figure 3A; Figure S2). Second, the absence of a protein from
controls was considered. Proteins were defined as high confi-
dence hits if they reached significance in the t test and were
absent from controls, while a protein was defined as a low abun-
dance hit if it was absent from controls but did not reach statis-
tical significance due to low intensity in the YnMyr samples. This
latter group is more likely to contain false positives in addition to
true hits.
In amastigotes, 81 proteins were significantly enriched (FDR
0.05) and, of these, 49 proteins were assigned as high confi-
dence using the definition above. A further 20 proteins were clas-
sified as low abundance hits (Table S1). In promastigotes, 134
proteins were significantly enriched (FDR 0.01) and, of these,
113 were high confidence; 28 proteins were assigned as low
abundance (Table S2). Notably, 59% of high confidence hits in
amastigotes did not contain an N-terminal glycine (MG),
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Figure 3. Proteomic Analysis of YnMyr Tagged Proteins in Leishmania
(A) Volcano plot showing the results of a two-sample t test (FDR 0.05, S0 1) applied to amastigote LFQ intensities to assess enrichment in YnMyr samples over
myristic acid controls (myr). MG, sequence contains an N-terminal glycine; high confidence, significant and absent from myr controls; low abundance, not
significant in the t test but absent from controls; other significant, significant at FDR 0.05 but also detected in myr controls; other, other proteins identified. See
also Figure S2.
(B) Comparison of YnMyr intensities of amastigote and promastigote hits (t test significant and low abundance hits) by t test (FDR 0.05, S0 2) after imputation of
missing values. Proteins are color coded to indicate those containing an N-terminal glycine (MG) and those found in only one of promastigote (Pro.) or amastigote
(Am.) data sets.
(C) Heatmap of YnMyr intensities across replicates for those MG proteins significantly differing between Am. and Pro.
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proposed to be a prerequisite of NMT-dependent myristoylation.
In promastigotes, this figure rose to 78%, suggesting that YnMyr
may not exclusively tag N-myristoylated proteins in Leishmania.
However, a number of proteins were indeed detected for which
there is prior experimental evidence for N-myristoylation in
Leishmania, including ARL1 (Sahin et al., 2008), SMP-1 (Tull
et al., 2004), CAP5.5 (Hertz-Fowler et al., 2001), and PPEF (Mills
et al., 2007). Other identifiedMG proteins include other ARF/ARL
proteins, Golgi reassembly stacking protein GRASP, several
other calpain-like cysteine peptidases, and protein phospha-
tases/kinases.
Probable integral membrane proteins were prominent in the
non-MG data sets; of the 107 significant non-MG hits in promas-
tigotes, 57 had predicted transmembrane (TM) helices, and of
the 58 non-MG hits in amastigotes, 28 had this feature (Tables
S1 and S2). Conversely, only 3 MG proteins across both data
sets had a predicted TM domain. S-Palmitoylation of TM pro-
teins is well known to occur in other eukaryotes (Blaskovic
et al., 2013) and it is possible that YnMyr is incorporated
into these proteins by palmitoyltransferases. Indeed, bio-
informatic analysis of the protein sequence suggested that
many hits that lacked the MG motif could be S-palmitoylated
(Figure S2; Table S3). Putative GPI-anchored proteins were
enriched by YnMyr tagging, including five uncharacterized pro-
teins (LdBPK_331200.1, LdBPK_352190.1, LdBPK_090690.1,
LdBPK_364340.1, LdBPK_350860.1), three surface antigens
(LdBPK_050900.1, LdBPK_051210.1, LdBPK_040180.1), and a
putative vacuolar-type proton translocating pyrophosphatase
(Table S3).
Comparison of hits (defined as proteins significantly enriched
over myristic acid controls or low abundance hits) in the two
L. donovani life stages showed high overlap of 67% (Table S3).
A t test was used to compare the YnMyr LFQ intensities of hits
(Figure 3B) revealing that select MG proteins are differentially ex-
pressed. Proteomic studies have revealed changes related to
the transition from promastigote to amastigote stage, in partic-
ular an increase in proteins associated with gluconeogenesis
and mitochondrial metabolism in amastigotes (Biyani and Mad-
hubala, 2012; Rosenzweig et al., 2008). The most strongly differ-
entially regulated putative N-myristoylated proteins identified
here are mostly proteins of unknown function, apart from
SMP-1 and sodium stibogluconate resistance protein, enriched
in promastigotes, and a putative protein kinase found only in
amastigotes (Figure 3C). Overall, likely N-myristoylated proteins
with important functions including transport, protein (de)phos-
phorylation, proteasomal degradation, and Golgi function are
conserved in both Leishmania life stages.
Chemical Knockdown of N-Myristoylation Defines NMT
Substrates
Although the global proteomic approach identified a number of
likely N-myristoylated proteins, the complexity of YnMyr labeling
in Leishmania complicates the firm assignment of specific pro-
teins as NMT substrates. We therefore sought to use chemical
knockdown of NMT in combination with YnMyr tagging to distin-
guish those proteins that are N-myristoylated from other lipi-
dated proteins, an approach recently used to define substrates
of the human NMTs in cancer cells (Thinon et al., 2014). Com-
pound 1 (Figure 4A) was first reported as a T. brucei NMT inhib-
itor with in vivo efficacy in a rodent model of trypanosomiasis
(Brand et al., 2012; Frearson et al., 2010), and we have subse-
quently shown that this inhibitor also acts on-target to inhibit
NMT in malaria parasites (Wright et al., 2014) and human cancer
cell lines (Thinon et al., 2014). Compound 1 has aKi
(app) (apparent
inhibition constant) of 2.5 nM against LdNMT and EC50s (half
maximal effective concentrations) of 7 mM and 23 mM against
Ld amastigotes and promastigotes, respectively (Paape et al.,
2014). Parasites were preincubated with 1 for 1 hr at varying con-
centrations and then YnMyr was added for 12 hr. Following
CuAAC, a drop in intensity in specific bands could be observed
in both life stages in response to inhibitor (Figures 4B and 4C).
Many bands were completely unaffected, possibly because
these proteins are not tagged via NMT activity, consistent with
the proteomic analyses above suggesting that YnMyr does not
label only N-myristoylated proteins. Blotting for HASPB after
pull-down revealed a dose-dependent decrease in the YnMyr
tagging of this protein (Figures 4B and 4C). These data suggest
that compound 1 inhibits NMT inside the cell.
While 1 translates very poorly from enzyme to cellular potency,
analog 2 shows similar enzyme inhibitory activity but is nearly 50-
fold more potent in the amastigote growth inhibition assay (Fig-
ure 4A). We hypothesized that this contrast could be explained
by the distinct physicochemical properties of the compounds,
which can affect uptake, efflux, and metabolism, or by off-tar-
gets of 2. Incubation with 2 at a concentration around its EC50
(0.2 mM) gave a similar decrease in YnMyr labeling to that
observed at the EC50 of 1 (7 mM) (Figure 4D), suggesting that
despite very different translation from recombinant enzyme to
cell potency, both inhibitors engage NMT inside the cell. As ex-
pected, a lower concentration of 1 (0.2 mM) resulted in only a par-
tial loss of specific labeling.
Inhibited samples were subject to pull-down, digest, and LC-
MS/MS. Biological and technical reproducibility of LFQ inten-
sities across replicates was high (R2 0.76–0.96 after imputation
of missing values; Figure S4) and the 580 proteins present in bio-
logical duplicates in the YnMyr samples were selected for further
analysis (Table S4). After filtering out nonspecific binders,
missing values were imputed. ANOVA (Benjamini Hochberg
correction, FDR 0.001) was used to compare across all four con-
ditions (YnMyr, 0.2 mM 2, 0.2 mM 1, and 7 mM 1) and permutation-
corrected t tests were used to compare each inhibition condition
with YnMyr controls. In all analyses therewas a significant reduc-
tion in intensity in a subset of MG proteins (Figure 5A; Table S4;
Figure S5). Relative to the YnMyr control, 30 proteins in the 7 mM
1 data set were significantly reduced and all contained an N-ter-
minal glycine.
Several bioinformatic tools (Bologna et al., 2004;Maurer-Stroh
et al., 2002) have been developed to predict N-myristoylation.
However, these tools are based on learning sets derived from
other eukaryotes and, of the MG proteins identified here as en-
riched through YnMyr tagging, the predictors disagreed on
whether a protein was a substrate in 30% of cases (Table S5).
In addition, several high confidence hits were assigned as non-
myristoylated by both tools, underlining the value of experi-
mental approaches to test bioinformatic predictions.
For those hits detected and assigned as significant at both
concentrations of inhibitor 1, there was a clear dose-dependent
decrease in intensity in response to 1 (Figure 5C). Several MG
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proteins showed no response and a subset of hits were signifi-
cantly decreased only at the higher concentration (7 mM) of 1
(Table S4). This latter group may contain proteins that are less
sensitive to NMT inhibition, possibly higher affinity substrates
(Thinon et al., 2014). Other proteins (Figure 5D) also did not
show strong responses to 1 and 2. All 16 proteins significantly
affected by inhibitor 2 were also hits in the 1 data set (Figure 5B;
Table S4). However, comparing the LFQ intensities of hits qual-
itatively and via a t test indicated that in fact 0.2 mM 2 did not
inhibitN-myristoylation as effectively as 7 mM 1 (Figure S5). A po-
tential explanation for this result is that 2 does inhibit NMT in
amastigotes but may have additional off-target effects that
slightly increase its potency in cells.
Since 7 mM 1 resulted in the strongest response, this data set
was used in combination with visual examination of heatmaps
to define high and low confidence hits (Table 1; Table S4; Fig-
ure 6A). All 30 proteins significant in the t test were defined as
high confidence NMT substrates since they showed either a
dose-response relationship or were absent from inhibited sam-
ples. Lowconfidence hitswere defined as those not reaching sig-
nificance in the t test but alsonot detected in the inhibited sample,
and include proteins expected to be N-myristoylated such as
GRASP, a calpain, and a serine/threonine phosphatase, but
also four proteins that havenoN-terminalMGmotif andsoare un-
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Figure 4. Effect of NMT Inhibition on YnMyr
Tagging
(A) Structures of inhibitors 1 and 2 and summary
of their activity against recombinant LdNMT
(apparent inhibition constant, Ki
(app)) and against
promastigotes (Pro.) or ex vivo amastigotes (Am.)
(half maximal effective concentration, EC50).
(B) Gel-based analysis of YnMyr tagging in pro-
mastigotes treated with inhibitor 1. Top: in-gel
fluorescence showing the effect of increasing 1
concentrations. Bottom: western blot (WB) of
HASPB following enrichment of YnMyr tagged
proteins by pull-down (PD) onto streptavidin
beads.
(C) Gel-based analysis of YnMyr tagging in
amastigotes treated with inhibitor 1. Top: in-gel
fluorescence showing the effect of increasing 1
concentrations. Bottom: WB of HASPB following
enrichment of YnMyr tagged proteins by PD onto
streptavidin beads.
(D) In-gel fluorescence analysis of YnMyr tagging
in amastigotes treated with inhibitor 1 or 2. Arrow
indicates most prominent loss of YnMyr tagging
upon inhibition. Full blots and Coomassie gels are
shown in Figure S3.
likely to be myristoylated. Of the 30 high
confidence proteins, 18 had been identi-
fied as significant or low abundance hits
in the global amastigote analysis, but a
further 11 had been identified in only one
or two replicates (Table S1), highlighting
the value of employing additional tools
to explore such complex samples.
To provide further insight into the
YnMyr modification of proteins, we used
the trypsin-cleavable site in AzRB to enable direct identification
of YnMyr-modified peptides. De novo-aided sequencing (Zhang
et al., 2012) was used to search for peptides containing the
YnMyr-AzRB-derived adduct at their N terminus. A total of 20
proteins were detected with this modification on a glycine resi-
due corresponding to the N terminus of the protein (Table S6),
and no peptides were identified in searches of myristic acid con-
trols. Of these 20 proteins, 8 had been identified as high confi-
dence NMT substrates via quantification of their response to
NMT inhibition and include known N-myristoylated protein
LdARL1, a proteasome subunit, a PP2C-like protein, a predicted
protein kinase and four uncharacterized proteins (Tables 1 and
S6; Figure 6A). An additional four lower confidence substrates
were also modified. Interestingly, modification on the N-terminal
glycine of three proteins (two fatty acyl-CoA ligases and unchar-
acterized LdBPK_300680.1) that did not respond robustly to
NMT inhibition was detected; these proteins may be NMT sub-
strates that are additionally modified elsewhere, for example,
at their enzyme active site or at alternative sites, or may bemodi-
fied on their N terminus by a mechanism distinct from NMT.
Several other modified proteins were identified that had not
been included in the global analyses due to weak detection.
Gene ontology analysis of the 30 high confidence NMT sub-
strates revealed that they have diverse functions and include
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phosphatases and kinases, proteins involved in transport and
degradation, as well as many (50%) proteins of unknown func-
tion (Figure 6B).
DISCUSSION
Here we combine chemical proteomic tools with inhibitors and
quantitative mass spectrometry to define the complement of
N-myristoylated proteins in L. donovani parasites, and explore
NMT as a potential drug target in this important human path-
ogen. Proteomic and gel-based analyses reveal that YnMyr is
incorporated into diverse sets of proteins, including N-myris-
toylated and GPI-anchored proteins, as well as into what are
most likely complex glycolipids. YnMyr incorporation into pro-
teins other than NMT substrates is not unprecedented; for
example, we observed significant YnMyr tagging of GPI-
anchored proteins in malaria parasites (Wright et al., 2014).
However, the proteomic analyses carried out here suggest
that while YnMyr does tag GPI-anchored proteins in Ld, these
are by no means the most abundant hits. A possibility is incor-
poration into S-acylation sites, since in mammalian cells YnMyr
and similar probes label both N-myristoylated and S-palmitoy-
lated proteins (Charron et al., 2009; Thinon et al., 2014) and
palmitoyltransferases have varying acyl-CoA specificities (Jen-
nings and Linder, 2012). Alternatively, YnMyr may be metabo-
lized to longer or shorter chain analogs retaining the alkyne
tag that are subsequently incorporated into proteins, or it
may be that alternative lipid modifications, such as the poorly
characterized lysine N-acylation (Lin et al., 2012), are prevalent
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Figure 5. Proteomics Analysis of YnMyr
Tagged Proteins in Amastigotes Treated
with NMT Inhibitors
(A) ANOVA test (Benjamini Hochberg correction,
FDR 0.001) applied to LFQ intensities to compare
inhibition conditions. The fold change in response
to 7 mM 1 is plotted against log10(p value). Pro-
teins above the dashed line reached significance
in this test. MG, sequence contains an N-terminal
glycine. Volcano plots of two-sample t tests are
shown in Figure S5.
(B) Comparison of LFQ ratios for 0.2 mM 2 and
7 mM 1 data sets after removal of nonspecific
binders. The proteins assigned as significantly
affected by both inhibitors are indicated. See
Figure S5 for direct comparison of these ratios by
t test.
(C) Response of selected MG proteins to 0.2 and
7 mM 1. Mean LFQ intensity before imputation of
missing values is plotted.
(D) MG proteins where YnMyr tagging does not
respond to NMT inhibition.
in Leishmania. Although enzymes with
lysine deacylase activity have been
described (Jiang et al., 2013), those
that carry out lysine acylation have not
been identified and it has been sug-
gested that such modifications may in
fact be nonenzymatic (Wagner and Hir-
schey, 2014). Leishmania may metabo-
lize YnMyr to a reactive intermediate that nonenzymatically
modifies proteins.
In addition to identification of lipidated proteins, we provide
evidence that compounds 1 and 2 inhibit NMT in live parasites.
While the potent in vitro activities of these compounds translate
to cellular activity rather poorly, and to very different extents, we
show here that this activity is accompanied by a drop in N-myr-
istoylation levels of specific proteins and thus provide the first
direct evidence for the druggability of NMT in Leishmania. Prob-
lems with translation from enzyme to cellular assays have been
reported previously in Leishmania, particularly in amastigotes
(Walker et al., 2011), but we anticipate that the methodology
developed here will be useful for screening NMT inhibitors for
target engagement inside the cell. Further experiments are
now required to confirm that the antiparasitic effects of inhibitors
1 and 2 arise solely through inhibition of NMT, and to identify
which NMT substrates mediate these effects.
The depth of coverage of the YnMyr tagged proteome identi-
fied could be improved; for example, HASPB, despite being de-
tectably tagged in gel-based analyses, was not identified in MS
studies; this may be due in large part to the sequence of this pro-
tein, which contains multiple repeats and is highly hydrophilic.
Several possible NMT substrates were detected but did not
meet the stringent filtering criteria applied and it is thus likely
that more NMT substrates remain to be validated in the future.
The set of proteins assigned as NMT substrates here is gener-
ally consistent with previous literature on N-myristoylated pro-
teins in Leishmania and other eukaryotes. Surprisingly, the
lipidation levels of CAP5.5 did not respond to inhibition of NMT
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Table 1. High and Low Confidence NMT Substrates Identified by Quantitative Proteomics with YnMyr in Combination with NMT
Inhibitors
Mean log2(LFQ intensity) is given and cells are color coded based on value. NaN, not a number (not found); Sig., significant. Proteins for which the
YnMyr-modified N terminus was detected are indicated. See also Tables S4 and S6.
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(Figure 5D; Table S4). CAP5.5 contains a strongly predictedmyr-
istoylation motif (Table S5) and its ortholog has been shown
experimentally to be N-myristoylated and S-palmitoylated in
T. brucei, the latter presumably on a nearby cysteine residue
(Hertz-Fowler et al., 2001). Similarly, although the phosphatase
PPEF did respond to NMT inhibition, basal YnMyr tagging was
still detectable (Table 1). There is evidence that PPEF is dually
acylated in L. major, with palmitoylation being dependent on
myristoylation, suggesting that in the absence of myristoylation
no labeling should occur (Mills et al., 2007). It is possible that
the relatively high concentration of YnMyr used here could force
incorporation into S-acylation or other sites, or that experimental
differences between studies may account for these different re-
sults; the dynamic nature of S-acylation may render labeling
highly dependent on incubation time and other culture condi-
tions. Alternatively, we cannot exclude the existence of another
enzyme with acyltransferase activity that carries out N-terminal
N-lipidation in Leishmania, although no experimental or bio-
informatic evidence has yet been reported to suggest this, and
there is no evidence for compensation on deletion of NMT in pro-
mastigotes (Brannigan et al., 2010).
Just over half of the 30 high confidence NMT substrates iden-
tified here are uncharacterized proteins, highlighting the huge
amount of NMT-related biology yet to be explored in Leishmania.
However, some predictions for the outcome of NMT inhibition
can be drawn from these data. ARF/ARL proteins, of which five
were identified as strongly affected by NMT inhibition, are impor-
tant mediators of intracellular trafficking in all eukaryotes and
their specific localization is often dependent onN-myristoylation.
LdARL1 is localized to the trans-Golgi network and involved in
control of endocytosis (Sahin et al., 2008); its T. brucei homolog
is also a Golgi protein essential in bloodstream parasites, where
its depletion causes defects in exocytosis and Golgi structure
(Price et al., 2005). TbARL6 is involved in flagellum extension,
interaction with microtubules, and the BBSome (Price et al.,
2012), which is important for specific trafficking events in all eu-
karyotes and is essential for virulence in Leishmania (Price et al.,
2013). Therefore basic cellular functions such as Golgi structure,
endo- and exocytosis are very likely to be affected by inhibition
of NMT, perhaps affecting parasite virulence. The identification
of three protein phosphatases, one kinase and phosphatidylino-
sitol phosphate kinase, suggests that signaling processes
dependent on specific (de)phosphorylation events will also be
disrupted. Finally, the proteasome has already been shown to
be a potential drug target in Plasmodium (Li et al., 2014) and
N-myristoylation of this subunit linked to function in yeast, where
removal of the myristoylation site causes proteasome mislocali-
zation, accumulation of misfolded protein, and growth defects
(Kimura et al., 2012). In summary, these data predict a strongly
pleiotropic effect of NMT inhibition on parasite cellular function
and provide evidence for NMT as a valid drug target in
Leishmania.
SIGNIFICANCE
The leishmaniases are a spectrum of neglected tropical dis-
eases for which few drugs are available and novel ap-
proaches are urgently required. A deeper understanding of
the underlying biology, and chemical validation, of potential
drug targets may improve the chances of successfully
developing new treatments. NMT catalyzes a specific and
essential lipidation of proteins in eukaryotes and the present
study explores protein lipidation in Leishmania donovani,
the causative agent of themost severe form of the leishman-
iases. We take advantage of the global picture afforded by a
chemical proteomic approach using a bioorthogonally
tagged lipid analog to show that protein lipidation in the
parasite is diverse and complex. To overcome this
complexity and identify NMT substrates, we quantify protein
lipidation levels in the presence of NMT inhibitors and sup-
port this with direct lipidation site identification. These
results predict pleiotropic effects of NMT inhibition in para-
sites and provide a method to assay for target engage-
ment in the cell. This work also constitutes the first global
experimental analysis of protein lipidation in Leishmania
and contributes a large proteomic data set for this
neglected human pathogen. These data may provide further
insights into other drug targets, for example, the complex
glycolipid pathways or individual functionally important
NMT substrates.
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EXPERIMENTAL PROCEDURES
Supplemental Experimental Procedures
The following procedures were carried out essentially as described previously
and details are given in the Supplemental Experimental Procedures: ex vivo
amastigote inhibition, macrophage cytotoxicity, and enzyme inhibition assays
(Hutton et al., 2014); sample preparation for proteomics analysis and LC-MS/
MS (Thinon et al., 2014).
Chemical Tools
The following chemical tools were synthesized as described previously:
YnMyr, YnPal, and AzTB (Heal et al., 2011); AzMyr and YnTB (Heal et al.,
2012); inhibitors 1 and 2 (Thinon et al., 2014). Synthesis of AzRB is given in
the Supplemental Experimental Procedures. Myristic and palmitic acids,
cycloheximide (CHX), and all other chemicals were purchased.
Ethics Statement
Animal experiments were approved by the University of York Animal Proce-
dures and Ethics Committee and performed under UK Home Office license
(Immunity and Immunopathology of Leishmaniasis Ref. no. PPL 60/3708).
Parasite Culture
The Ethiopian LV9 strain of Leishmania donovani (MHOM/ET/67/L28) was
maintained by serial passage in Rag-2/ mice. Amastigotes were extracted
from spleen as described previously (Smelt et al., 1997) and cultured in
RPMI/10% fetal calf serum (FCS). Promastigotes were obtained by transform-
ing 1 3 107 freshly isolated amastigotes in promastigote medium (St-Denis
et al., 1999) at 26C (2 days for transformation). Promastigotes were
passaged twice a week for up to 10 passages. Further details are given in
the Supplemental Experimental Procedures.
Metabolic Tagging Experiments
Promastigotes were cultured in RPMI/10% FCS containing the appropriate
probe (50 mM YnMyr, myristic acid, or as indicated) at a parasite density of
7.5 3 107 parasites/ml. Cultures were incubated at 26C for 12 hr (or as indi-
cated). Cells were collected (800 3 g, 15 min, 4C), washed twice with cold
PBS, then lysed at 1 3 109 parasites/ml by sonication on ice (4 3 10 s burst,
amplitude 45 with 1 min interval) in 1% NP40, 1% sodium deoxycholate,
0.5% SDS, 50 mM Tris (pH 7.4), 150 mM NaCl, EDTA-free protease inhibitor.
Insoluble material was separated by centrifugation (16,100 3 g, 30 min, 4C).
Tagging of ex vivo amastigotes was carried out as above but parasites were
cultured at 37C. For inhibition studies, the appropriate inhibitor was preincu-
bated with parasite culture for 1 hr at 37C, parasites pelleted and resus-
pended in fresh medium containing inhibitor plus probe (YnMyr etc). Further
details are given in the Supplemental Experimental Procedures.
Intracellular Amastigote Tagging
BALB/c mice were obtained from Charles River. Macrophages (BMDM) were
differentiated from bone marrow of BALB/c mice as described previously
(Weinheber et al., 1998) andplatedout at 13 106 cells perwell in six-well plates.
BMDMswereadheredovernightand then infectedat amultiplicity of infectionof
10 with freshly isolated L. donovani amastigotes (see above). After 24 hr no free
parasites were observed. Tagging was performed for 18 hr with YnMyr or myr-
istic acid at a final concentration of 100 mM.Cells werewashed three timeswith
PBS at room temperature (RT) before 300 ml of lysis buffer was added and cells
scraped off. The lysate was sonicated (33 10 s, amplitude 45 with 1 min inter-
vals), then centrifuged for 30 min at 16,100 3 g at 4C. The supernatant was
transferred into a fresh tube and flash frozen in liquid nitrogen. BMDMs were
maintained in DMEM supplemented with 4 mM L-glutamine and 4% L929-
cell conditionedmedium.All experimentswereperformedat 37Cand5%CO2.
CuAAC Labeling and Pull-down
Proteins were precipitated with chloroform/methanol (MeOH:CHCl3:ddH2O
4:1:3), or acetone (4 volumes at 20C for 1 hr) and then resuspended at
1 mg/mL in 1% SDS in PBS. This precipitation step was found to increase
labeling intensity after CuAAC. Premixed click reagents (100 mM AzTB,
1 mM CuSO4, 1 mM TCEP, 100 mM TBTA, final concentrations) were added
(Heal et al., 2012) and samples vortexed for 1 hr at RT, then quenched by
the addition of 10 mM EDTA. Proteins were precipitated again with MeOH/
CHCl3 or with 10 volumes of MeOH (overnight at 80C), washed with ice-
cold MeOH, air-dried, and resuspended in 2% SDS, 10 mM EDTA in PBS.
For direct gel analysis, 43 sample loading buffer (NuPAGE LDS sample buffer)
with 2-mercaptoethanol (4% final) was added. For hydroxylamine (NH2OH)
and NaOH treatment, samples were treated with 1 M NH2OH (pH 7) or 0.2 M
NaOH at RT for 1 hr. Samples were quenched by addition of 43 sample
loading buffer. Note that addition of EDTA to the samples before NH2OH treat-
ment is important to avoid sample degradation. Proteins were heated for 3 min
at 95C prior to SDS-PAGE. Pull-down was carried out with Dynabeads
MyOne Streptavidin C1 as described previously (Wright et al., 2014) (see Sup-
plemental Experimental Procedures).
Gel and Western Blot Analysis
Samples were separated by SDS-PAGE and scanned with Cy3 filters to detect
the TAMRA fluorophore using an Ettan DIGE scanner (GE Healthcare).
For western blot, proteins were transferred from gels to polyvinylidene fluo-
ridemembrane (Immobilon-PSQ,Millipore) using a semidry system (Invitrogen).
Following blocking (5% milk in Tris-buffered saline, 1% Tween), membranes
were incubated with primary antibody for 1 hr at RT or overnight at 4C in
blocking solution, then incubated with secondary antibody (goat anti-rabbit
IgG-HRP, Invitrogen, 1:10,000) for 1 hr in blocking solution. Detection was
carried out using Luminata Crescendo Western HRP substrate (Millipore) ac-
cording to the manufacturer’s instructions and on a Fujifilm LAS 3000 imager.
Primary antibodies, LdHASPB (rabbit; ab 2-AE) (Alce et al., 1999), LmHASPB
(rabbit, 336) (Alce et al., 1999), GP63 (rabbit, polyclonal; provided by
R. McMaster, University of British Columbia) (Frommel et al., 1990), GFP
(mouse, Santa Cruz), were used at 1:1,000–2,000.
Proteomic Data Searching and Analysis
Data Searching and Analysis
The data were processed with MaxQuant version 1.3.0.5 and the peptides
were identified from the MS/MS spectra searched against The TriTrypDB-
6.0 L. donovani LdBPK282A1 database using the Andromeda search engine.
The protein HASPB was not present in this database and so the Uniprot
sequence (O77300_LEIDO) was appended to the FASTA file. Cysteine carba-
midomethylation was used as a fixed modification and methionine oxidation
and N-terminal acetylation as variable modifications. The false discovery
rate was set to 0.01 for peptides, proteins, and sites. Other parameters were
used as preset in the software. ‘‘Unique and razor peptides’’ mode was
selected to allow for protein grouping; this calculates ratios from unique and
razor peptides (razor peptides are uniquely assigned to protein groups and
not to individual proteins). Data were elaborated using Perseus versions
1.4.0.20 and 1.5.0.31. LFQ experiments in MaxQuant were performed using
the built-in label-free quantification algorithm (Cox et al., 2014).
Modified Peptide Identification
MSdata were processedwith PEAKS7 suite (Zhang et al., 2012) The data were
searched against a reference L. donovani database fromUniprot (27/11/2014).
Trypsin (specific, up to threemissed cleavages allowed) was selected for data-
base searches and no enzymewas chosen for de novo searches. Themaximal
mass error was set to 5 ppm for precursor ions and 0.01 Da for product ions.
Carbamidomethylation was selected as a fixed modification and methionine
oxidation as well as the lipid-derived adduct (+534.3278 Da) to any amino
acid at peptide N terminus were set as variable modifications. The maximal
number of modifications per peptide was set as five. The false discovery rate
was set to 0.01 for peptides andb1 ionswere required for N-terminallymodified
peptides.Within PEAKS, amodule called SPIDER searches for pointmutations
to further enhance the discovery (Ma and Johnson, 2011).
Data Processing: YnMyr Tagged Proteins in Amastigotes and
Promastigotes
For amastigotes, four replicates were performed independently, starting from
the same metabolically labeled lysates (Myr and YnMyr samples). Data were
filtered to require three valid values across the four replicates, label-free inten-
sities were logarithmized (base 2), and empty values were imputed with
random numbers from a normal distribution, whosemean and SDwere chosen
to simulate low abundance values close to noise level (impute criteria: width
0.1, downshift 1.8). A modified t test with permutation-based FDR statistics
was applied (250 permutations; FDR 0.05; S0 1).
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For promastigotes, three replicates were performed independently, starting
from the same metabolically labeled lysates (Myr and YnMyr samples). Data
were analyzed as described above with three valid values per group
required, imputation (width 0.1, downshift 1.8), and t test (250 permutations;
FDR 0.01; S0 1).
For the comparison of amastigotes and promastigotes, data were filtered for
at least three valid values in at least one group (groups: Am_Myr, Am_YnMyr,
Pro_Myr, Pro_YnMyr). YnMyr intensities of hits (proteins that were either t test
significant or classed as low abundance hits in the independent analyses) were
compared by t test (250 permutations; FDR 0.05; S0 2) after imputation of
missing values (width 0.1, downshift 2.5). Hierarchical clustering was carried
out in Perseus.
Data Processing: YnMyr Tagging in the Presence of NMT Inhibitors
(Amastigotes)
Independent biological experiments were carried out where amastigotes were
incubated with YnMyr, YnMyr + 0.2 mM 2, YnMyr + 0.2 mM 1, or YnMyr + 7 mM
1. A Myr control was included in one of these experiments. For proteomics
analysis, all samples were prepared and processed in duplicate (technical rep-
licates: A and B; C and D). The ‘‘Match between runs’’ option (time window
2 min) in MaxQuant was enabled during the searches. Data were grouped,
filtered to retain only those proteins present in both biological experiments,
and nonspecific binders (enrichment over control <2) removed. Missing values
were imputed from a normal distribution (width 0.1, downshift 1.8) and modi-
fied two-sample t tests were applied (250 permutations; FDR 0.001; S0 1).
ANOVA (Benjamini Hochberg correction, FDR 0.001) was also applied to
LFQ intensities to compare across all data sets.
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Supplemental Figures and Tables 
Supplemental Figures 
Figure S1: Additional gel-based data and controls, related to Figures 1 & 2. Time-dependent 
labeling; competition with myristic acid; sensitivity of labeling to cycloheximide treatment; 
hydroxylamine treatment of lysates; YnMyr tagging of GP63; YnMyr tagging in L. major 
18AA-HASPB-GFP strains; structures of AzTB and YnTB. 
Figure S2: Proteomics data related to Figure 3. Volcano plots of YnMyr proteomics (t-test); 
prediction of S-palmitoylation for non-MG hits in amastigotes and promastigotes. 
Figure S3: Inhibition full gel and blot data, including controls related to Figure 4. 
Figure S4: Scatter plots to assess biological and technical reproducibility of inhibition 
proteomics experiments related to Figure 5. 
Figure S5: Inhibitor proteomics additional data related to Figures 5 & 6. 
Figure S6: YnMyr modified peptide, assigned spectra related to Figure 6 and Table 1. 
Supplemental Tables 
Supplemental Tables are provided as separate Excel spreadsheets. 
Table S1: Identification of YnMyr tagged proteins in amastigotes related to Figure 3. 
Identification of proteins following metabolic tagging with Myr or YnMyr, CuAAC, pull-down, 
tryptic digest and LC-MS/MS analysis. Four replicates were performed independently, 
starting from the same metabolically labelled lysates (Myr and YnMyr samples). Data 
processing is described In Supplemental Procedures below (Data processing: YnMyr tagged 
proteins in amastigotes and promastigotes). 
Table S2: Identification of YnMyr tagged proteins in promastigotes related to Figure 3. 
Identification of proteins following metabolic tagging with Myr or YnMyr, CuAAC, pull-down, 
tryptic digest and LC-MS/MS analysis. Three replicates were performed independently, 
starting from the same metabolically labelled lysates (Myr and YnMyr samples). Data 
processing is described In Supplemental Procedures below (Data processing: YnMyr tagged 
proteins in amastigotes and promastigotes). 
Table S3: Comparison of proteomics in promastigotes and amastigotes, and 
bioinformatic annotation of hits; related to Figure 3. The datasets shown in Tables S1 & 
S2 were compared. GPI-anchor and S-palmitoylation prediction was carried out for hits. Data 
processing is described In Supplemental Procedures below (Data processing: YnMyr tagged 
proteins in amastigotes and promastigotes). 
Table S4: YnMyr proteomics in the presence of NMT inhibitors related to Figures 5 & 
6. Amastigotes were metabolically tagging with Myr or YnMyr in the presence of inhibitors 1 
or 2 at indicated concentrations; CuAAC, pull-down, tryptic digest and LC-MS/MS analysis 
were performed to identify proteins. Two technical replicates (sample preparation from the 
lysates) of two biological replicates were carried out. Data processing is described In 
Supplemental Procedures below (Data processing: YnMyr tagging in the presence of NMT 
inhibitors (amastigotes)). 
3 
 
Table S5: All N-terminal glycine-containing (MG) L. donovani proteins; related to 
Figures 3, 5 & 6. Prediction of N-myristoylation by bioinformatic tools and cross-referencing 
to current study was performed for all L. donovani MG proteins in the database. 
Table S6: Identification of YnMyr modified peptides, related to Figure 6 and Table 1. 
Proteomic data were further analyzed by de novo-aided sequencing to identify peptides 
modified by the the lipid-derived adduct (+534.3278 Da) on any amino acid at peptide N-
terminus. All peptides reported are N-terminal peptides unique for the protein that they were 
assign to by the software.
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Figure S1. Additional labeling data for L. donovani promastigotes. Related to Figs. 1 & 2. A. Ld 
promastigotes were cultured for the indicated timepoints in the presence of myristic acid (M) or 
YnMyr (Yn), lysed and proteins subject to CuAAC reaction and analysis by in-gel fluorescence. B. 
Promastigotes were labeled with YnMyr in the presence of varying amounts of myristic acid (Myr). 
C. YnMyr incorporation into proteins is dependent on protein synthesis, but incorporation into 
putative glycolipid is less affected. Promastigotes were tagged with myristic acid (-) or YnMyr in the 
presence of 50 μM cycloheximide (CHX) for indicated timepoints and samples processed by 
CuAAC. D. Treatment of YnMyr tagged samples with base (NaOH) or hydroxylamine (HA; pH7). 
C/M: precipitation with CHCl3/MeOH. E. Analysis of YnMyr tagged samples by Western blot for GPI-
anchored protein GP63 after CuAAC and pull-down. Click: sample reacted with CuAAC reagents; 
PD B: sample pulled-down onto streptavidin-coated beads and proteins eluted from beads by 
boiling. * = non-specific band, streptavidin monomer. Note that the percentage incorporation of 
YnMyr is clearly low, as it must compete with endogenous lipid. Numbers are molecular weight 
markers in kDa. F. Related to Fig. 2; total protein labeling in HASPB GFP-fusion strains. G. 
Structures of AzTB and YnTB. 
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Figure S2: YnMyr proteomics in amastigotes and promastigotes; related to Fig. 3. Permutation-corrected two-sample t-tests were applied to compare 
YnMyr and myristic acid (Myr) controls after imputation of missing values. An LFQ enrichment ratio was calculated from the ratio of YnMyr and Myr 
LFQ intensities (mean). ‘High confidence’: protein significant and absent from controls; ‘low abundance’: protein absent from myristic acid controls but 
did not reach statistical significance due to low intensity in the YnMyr samples; ‘Other significant’: protein significant but present in controls A. T-test in 
promastigotes. The 274 proteins present in all three replicates. T-test: FDR = 0.01, S0 = 1, 250 permutations. B. T-test in amastigotes. T-test: FDR = 
0.05, S0 = 1, 250 permutations. C. & D. Volcano plots with prediction of S-palmitoylation using CSS-Palm (Ren et al., 2008) indicated for non-MG 
proteins in amastigotes and promastigotes (see also Supp. Table S3). 
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Figure S3: Related to Fig. 4; full blots and control gels for inhibition experiments. A. 
Coomassie (CB) staining for the gel shown in Fig. 4B. B. Western blot against HASPB 
(portion of image boxed with dashed line is shown in Fig. 4B) before and after pull-down of 
HASPB onto streptavidin beads after CuAAC in promastigotes. Four-fold more protein is 
loaded after pull-down compared to before. C. Coomassie staining for the gel shown in Fig. 
4C. D. Western blots against HASPB before and after pull-down of HASPB in amastigotes. 
Four-fold more protein loaded after pull-down compared to before. Top and bottom are 
replicate experiments performed independently starting from the same lysate. E. 
Independent biological experiment processed in the same way as those in D. Numbers are 
molecular weights in kDa. 
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Figure S4: Related to Fig. 5. Multiscatter plots to assess biological and technical reproducibility of replicate 
inhibition proteomics samples. A & B: technical replicates of first biological replicate; C & D: technical 
replicates of second biological replicate. Dataset consists of 580 proteins identified in both independent 
biological experiments; Log2(LFQ intensity) is plotted after imputation of missing values. Numbers in the top 
left corner of each plot indicates R2 value (correlation); proteins containing an N-terminal glycine are 
coloured red, other proteins are black. 
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Figure S5: YnMyr inhibition proteomics; related to Figs. 5 & 6. A. T-test comparing 7 μM 1 (left) or 0.2 μM 1 
(right) and YnMyr datasets, after removal of non-specific binders. FDR = 0.001, S0 = 1, 250 permutations. 
B. T-test comparing 0.2 μM 2 and YnMyr datasets, after removal of non-specific binders. FDR = 0.001, S0 
= 1, 250 permutations. C. T-test comparing response to 0.2 μM 1 and 7 μM 1: a ratio of LFQ intensities for 
YnMyr/(inhibitor treatment) was calculated for each replicate experiment (A-D) and a two-sample t-test 
(FDR 0.05, S0 1) performed to compare the response to the two inhibitors. D. Profile plots of the response 
of selected MG proteins to inhibition. Log2(mean LFQ intensity) across four replicates. As for main text 
Figure 5C but including data for 0.2 μM 2. 
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Figure S6: assigned spectra for YnMyr modified peptides. Related to Fig. 6 and Table S6. 
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Supplemental Experimental Procedures 
Synthesis of AzRB 
Capture reagent AzRB was synthesised by solid phase peptide synthesis on a Biotin-PEG 
NovaTag™ resin (Novabiochem®). Fmoc-protected amino acids and coupling reagents 
were sourced from AGTC Bioproducts. Azidoacetic acid was sourced from Sigma Aldrich. 
Ultrapure water was obtained from a MilliQ Millipore water purification system. LC-MS 
analysis and purification was performed on a Waters HPLC system fitted with a Waters 515 
HPLC pump, Waters 2767 autosampler, Waters XBridge C18 4.6 mm × 100 mm (analytical) 
or 19mm × 100 mm (preparative) column, Waters 3100 mass spectrometer and Waters 
2998 photodiode array. NMR was performed on a Bruker AV-400 instrument. High resolution 
mass spectrometry was performed by the Imperial College Department of Chemistry Mass 
Spectrometry Service. 
The resin (208 mg, 100 µmol) was placed in a fritted syringe and swollen in DMF for 30 min 
before Fmoc deprotection in 20% piperidine/DMF (3 mL, 3 x 3 min).  The resin was washed 
in DMF (3 x 3mL), DCM (3 x 3 mL) and DMF (3 x 3mL) after which Fmoc-ε-Ahx-OH (177 mg, 
500 µmol), Fmoc-Gly-OH (149 mg, 500 µmol), Fmoc-Arg(Pbf)-OH (324 mg, 500 µmol), 
Fmoc-Ala-OH (156 mg, 500 µmol) and azidoacetic acid (37 µL, 500 µmol) were double-
coupled sequentially. The coupling of Fmoc-ε-Ahx-OH was performed using HATU (186 mg, 
490 µmol) and DIPEA (174 µL, 1.0 mmol) and for all other residues HBTU (186 mg, 490 
µmol) and DIPEA (174 µL, 1.0 mmol) were used. Each coupling was performed as follows: 
the amino acid and coupling reagents were dissolved in DMF (2 mL) and activated for 5 min 
before addition to the resin. The resin was shaken for 1-3 hours, washed in DMF (3 x 3mL), 
DCM (3 x 3 mL) and DMF (3 x 3 mL). A fresh batch of activated amino acid was added and 
the resin shaken for a further 1-3 hours. After washing, Fmoc deprotection was performed as 
above, followed by washing. The procedure was then sequentially repeated for each 
residue, finishing with the coupling of the azidoacetic acid moiety, which required no Fmoc 
deprotection. After the final coupling the resin was washed in DMF (3 x 3 mL), DCM (3 x 3 
mL), MeOH (3 x 3 mL) and Et2O (3 x 3 mL) and dried under vacuum overnight. The capture 
reagent was cleaved from the resin by incubation in a solution of 95% TFA, 2.5% TIS and 
2.5% DTT (3 mL) for 3 hours. The cleavage mixture containing the cleaved product was 
transferred into a 15 mL falcon tube, and the resin washed twice with cleavage mixture (0.5 
mL). The solution was concentrated to a volume of 1 mL under a stream of nitrogen, after 
which the product was precipitated by addition of ice-cold tert-butyl methyl ester (TBME) (10 
mL). The product was pelleted by centrifugation. The pellet was washed twice with TBME 
(10 mL) and dried overnight in a vacuum dessicator. The pellet was resuspended in 
ultrapure water and purified by preparative RP-HPLC in a gradient of methanol and water 
both supplemented with 0.1% formic acid (0-10 min 5-98% MeOH, 10-12 min 98% MeOH). 
The fractions containing product were combined and the solvents removed by speedvac. 
The product was resuspended in ultrapure water (1 mL) and lyophilised to dryness to yield a 
white solid (24.3 mg, 26 µmol, 26%). 
23 
 
 
δH/ppm (400 MHz, D2O) 8.39 (s, 1H), 4.58 (dd, J = 7.9, 4.8 Hz, 1H, H56), 4.40 (dd, J = 8.0, 
4.4 Hz, 1H, H55), 4.36 – 4.23 (m, 2H, H8 & H5), 4.02 (s, 2H, H22), 3.93 – 3.77 (m, 2H, H2), 
3.73-3.59 (m, 8H), 3.55 (2xt, J = 6.4, 4H), 3.31 (dt, J = 9.7, 5.1 Hz, 1H, H37), 3.27 – 3.09 (m, 
8H), 2.97 (dd, J = 13.1, 5.0 Hz, 1H, ½H39), 2.75 (d, J = 13.2 Hz, 1H, ½H39), 2.22 (2xt, J = 
7.6 Hz, 4H), 2.03 – 1.17 (m, 23H); δC/ppm (100 MHz, CD3OD) 175.99, 175.94, 175.34, 
174.14, 171.21, 170.52, 170.26, 166.09 (6 x C=O, 1 x C=O tautomer), 158.65 (C17), 71.53 
(2xC), 71.23 (2xC), 69.91 (2xC), 63.39, 61.62, 57.04, 54.53, 52.52, 50.98, 43.39, 41.95, 
41.06, 40.30, 37.82 (2xC), 37.02, 36.86, 30.45 (2xC), 29.99, 29.82, 29.59, 29.53, 27.49, 
26.92, 26.68, 26.15, 17.66; HRMS, m/z (ESI) found 927.5200 (C39H71N14O10S, [M + H]
+, 
requires 927.5198). 
Parasite culture (extra detail) 
Animal experiments were approved by the University of York Animal Procedures and Ethics 
Committee and performed under UK Home Office licence (‘Immunity and Immunopathology 
of Leishmaniasis’ Ref # PPL 60/3708). 
The Ethiopian strain of Leishmania donovani (MHOM/ET/67/HU3, also known as LV9) was 
maintained by serial passage in Rag-2-/- mice. Rag-2-/- mice were bred in-house, housed 
under specific pathogen-free conditions and used at 6–12 weeks of age. Amastigotes were 
extracted from spleen as described previously (Smelt et al., 1997): briefly, the spleen was 
removed into unsupplemented RPMI, transferred to a homogeniser and topped up with 
RPMI medium (approx. 40 mL). The spleen was homogenised to a single cell suspension, 
transferred to a tube and centrifuged at 800 rpm for 5 minutes; the supernatant was retained. 
A 50 mL falcon tube was coated with 25 mg saponin per 40 mL supernatant, the supernatant 
poured in, mixed and left to stand at RT for 5 min. The tube was centrifuged at 3100 rpm for 
10 min and supernatant discarded. The pellet was washed 3× by resuspending in 25 mL 
RPMI and centrifuging at 3100 rpm for 10 minutes. The washed pellet was resuspended in 
20 mL RPMI with 10% FCS. 
Mice were infected with 3×107 L. donovani amastigotes intravenously (i.v.) via the tail vein in 
200 μl of RPMI 1640 (GIBCO, Paisley, UK). 
Promastigotes were obtained by transforming 1×107 freshly isolated amastigotes in 
promastigotes medium (St-Denis et al., 1999) at 26 °C (~2 days for transformation). 
Parasites were maintained in T25 flasks with non vented lids containing 10 mL medium and 
passaged twice a week for up to 10 passages. 
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RPMI medium for L. donovani promastigote culture (St-Denis et al., 1999): RPMI 1640 
(Sigma #R6748), containing 20 % FCS, 1 % Pen/Strep, 100 μM adenine, 20 mM MES (pH 
5.5 with NaOH), 5 μM hemin, 3 μM biopterin and 1 μM biotin. 
Metabolic tagging experiments (extra detail) 
Promastigotes were pelleted by centrifugation at 800 ×g, 15 min, 26 °C, and resuspended in 
RPMI/10% FCS containing the appropriate probe (50 μM YnMyr, or myristic acid, 100 μM 
AHA etc, unless otherwise indicated; from 100 mM stocks) at a parasite density of 7.5×107 
parasites/mL. Cultures were incubated at 26 °C for 12 hours (or as indicated). Cells were 
pelleted by centrifugation 800 ×g, 15 min, 4 °C, washed twice with cold PBS then pelleted at 
3200 rpm for 10 min at 4°C. After removal of the supernatant, cells were lysed in lysis buffer 
(1 % NP40, 1% sodium deoxycholate, 0.5 % SDS, 50 mM Tris pH 7.4, 150 mM NaCl, EDTA-
free protease inhibitor, Roche) at 1×109 parasites/mL by sonication on ice (4× 10 sec burst, 
amplitude 45 with 1 min interval). Insoluble material was separated by centrifugation at 
16,100 ×g for 30 min at 4°C, the supernatant transferred to fresh tubes and snap frozen in 
liquid N2, then stored at -80 °C. Tagging of ex vivo amastigotes was carried out as above but 
parasites were cultured at 37 °C. 
For inhibition studies, the appropriate inhibitor was pre-incubated with parasite culture for 1 h 
at 37°C, parasites pelleted by centrifugation at 2200 ×g, 10 min, supernatant removed and 
parasites resuspended in fresh medium containing inhibitor plus probe (YnMyr, myristic acid 
etc). 
Ex vivo amastigotes inhibition assay 
As described in (Hutton et al., 2014). Briefly, L. donovani amastigotes 
(MHOM/ET/67/L28/LV9) isolated from the spleens of infected Rag-2-/- mice were placed in 
96 well plates at a density of 4×105 ex vivo amastigotes per well in a total volume of 200 µL 
of supplemented RPMI 1640 medium (see ‘promastigote medium’, above) containing test 
compounds diluted over a threefold range. After incubation for 72 hr at 26 °C, 20 µL of an 
Alamar blue solution (Trek Diagnostics) was added and plate incubated for a further 6 hr at 
26°C. Fluorescence per well was measured using a POLARstar Optima instrument (BMG 
labtech; ex.: 544 nm, em.: 590 nm). All assays were run in triplicate and the data analysed 
by a standard package (GraphPad Prism v5). 
Macrophage cytotoxicity assay 
As described in (Hutton et al., 2014). Briefly, compounds were tested in parallel against 
mouse primary macrophages (Alamar blue assay) in triplicate, and analysed as above. In 
brief, primary macrophages derived from BALB/c bone marrow were seeded into 96 well 
plates at 4.2×104 macrophages/well in a total volume of 200 µL (DMEM (Invitrogen, UK), 
10% FCS, 4% L-929 cell conditioned supernatant). Compounds diluted over a threefold 
range were added, with assays run in duplicate. After incubation for 72 hr at 37°C/5% CO2, 
20 µL Alamar blue was added and the plate incubated for a further 6 hr at 37°C/5% CO2, 
prior to fluorescence measurements as above. 
CuAAC labeling and pull-down 
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Proteins were precipitated with chloroform/methanol (MeOH:CHCl3:ddH2O 4:1:3), or acetone 
(4 vol. -20 °C 1 h) and then resuspended at 1 mg/mL in 1 % SDS in PBS. This precipitation 
step was found to increase labeling intensity after CuAAC, likely due to the presence of 
probe-incorporating glycolipids in the lysates (see main text). Premixed click reagents (100 
µM AzTB, 1 mM CuSO4, 1 mM TCEP, 100 µM TBTA, final concentrations) were added as 
described previously (Heal et al., 2012) and samples vortexed for 1 h RT, then quenched by 
the addition of 10 mM EDTA. Proteins were precipitated again with MeOH/CHCl3, washed 
with ice-cold MeOH, air-dried for ~15 min, and then resuspended in 2 % SDS, 10 mM EDTA 
in PBS. For direct gel analysis, 4 x sample loading buffer (NuPAGE LDS sample buffer) with 
2-mercaptoethanol (4 % final) was added and proteins heated for 3 min at 95 °C prior to 
SDS-PAGE. 
For hydroxylamine (NH2OH) and NaOH treatment, samples were resuspended after CuAAC 
as above, then 1 M NH2OH pH7 or 0.2M NaOH added and samples incubated at RT for 1 
hour. Samples were quenched by addition of 4 x sample loading buffer. Note that addition of 
EDTA to the samples before NH2OH treatment is important to avoid sample degradation.  
For pull-down, protein was resuspended at 10 mg/mL in 2 % SDS, 10 mM EDTA in PBS, 
and then diluted to 1 mg/mL with PBS. DTT (from a fresh 100 × stock in water) was added to 
give a final concentration of 1 mM. Proteins were incubated with Dynabeads® MyOne™ 
Streptavidin C1 (pre-washed 3 × 0.2 % SDS in PBS) for 1.5-2 h at RT with rotation. 
Following removal of the supernatant, beads were washed with 3 × 1 % SDS in PBS, then 
boiled for 10 mins in sample loading buffer elute bound proteins. 
Gel and Western blot analysis 
Samples were separated by SDS-PAGE and the gel soaked in fixing solution (10 % AcOH, 
40 % MeOH), then rinsed in water for in-gel fluorescent imaging: gels were scanned with 
Cy3 filters to detect the TAMRA fluorophore using an Ettan DIGE scanner, GE Healthcare. 
Molecular weight markers (Precision Plus All Blue Standards, Bio-Rad) were detected with 
Cy5 filters. 
For Western blot, proteins were transferred from gels to PVDF membrane (Immobilon-PSQ, 
Millipore) using a semi-dry system (Invitrogen). Following blocking (5 % milk in TBS, 1% 
Tween), membranes were incubated with primary antibody for 1 hour at room temperature or 
overnight at 4°C in blocking solution, then incubated with secondary antibody (goat anti-
rabbit IgG-HRP, Invitrogen, 1:10000) for 1 hr in blocking solution. Detection was carried out 
using Luminata Crescendo Western HRP substrate (Millipore) according to the 
manufactures instructions and on a Fujifilm LAS 3000 imager. Primary antibodies, LdHASPB 
(rabbit; ab 2-AE) (Alce et al., 1999), LmHASPB (rabbit, 336) (Alce et al., 1999), GP63 
(rabbit, polyclonal; provided by R. McMaster, University of British Columbia) (Frommel et al., 
1990), GFP (mouse, Santa Cruz), were used at 1:1000-2000. 
Proteomics experiments 
Pull-down and preparation of peptides for MS. Proteins were captured by CuAAC as 
before with the following modifications: CuAAC reaction was carried out for 2 hours and, for 
some samples, with AzRB in place of AzTB. When AzRB was used, proteins were 
precipitated following CuAAC via a modified chloroform/methanol precipitation procedure: 4 
volumes of MeOH, 1 vol. CHCl3, 3 vol. H2O were added to the sample, which was 
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centrifuged at 17,000 ×g for 5 min to pellet proteins at the interface. Both layers were then 
removed simultaneously, the pellet resuspended in 0.2 % SDS/PBS to the original volume 
and the precipitation procedure repeated. The pellet was then washed twice with MeOH. 
Resuspension and affinity enrichment were performed for all samples as before with the 
following modifications: NeutrAvidin agarose resin (Thermo Scientific, pre-washed 3 × 0.2 % 
SDS in PBS; typically 50 μL of bead slurry was used for 0.5 mg of lysate) was used in place 
of the magnetic Dynabeads due to increased stability of the resin during on-bead reduction 
and alkylation of proteins. Beads were stringently washed following pull-down: 3 × 1 % SDS 
in PBS, 3 × 4M Urea in 50 mM PBS, 5 × AMBIC (50 mM ammonium bicarbonate). For a 50 
μL bed of beads resuspended in 50 μL AMBIC, samples were reduced (5 μL of 100 mM DTT 
in 50 mM AMBIC) at 60 °C for 30 minutes and allowed to cool to room temperature. The 
beads were washed with 2 x AMBIC. Cysteines were alkylated (5 μL of 100 mM 
iodoacetamide in AMBIC) at room temperature for 30 min in the dark. The beads were 
washed with 2 x AMBIC. Trypsin (3 μg Sequencing Grade Modified Trypsin (Promega) 
dissolved at 0.2 μg/μL in AMBIC per mg starting lysate) was added to the beads and 
samples were placed on a shaker and digested overnight at 37 °C. The samples were 
centrifuged and the supernatant was transferred into clean tubes. The beads were washed 
twice with 0.1% aqueous formic acid, and these washes were combined with the first 
supernatant. The solutions were stage-tipped according to a published protocol (Rappsilber 
et al., 2003). Elution from the sorbent (SDC-XC from 3M) with 70 % acetonitrile in water was 
followed by speed-vac-assisted solvent removal, reconstitution of peptides in 0.5 % TFA, 2 
% acetonitrile in water, and transferred into LC-MS sample vials. 
LC-MS/MS analysis. The analysis was performed using an Acclaim PepMap RSLC column 
50 cm × 75 μm inner diameter (Thermo Fisher Scientific) using a 2 h acetonitrile gradient in 
0.1 % aqueous formic acid at a flow rate of 250 nL/min. Easy nLC-1000 was coupled to a Q 
Exactive mass spectrometer via an easy-spray source (all Thermo Fisher Scientific). The Q 
Exactive was operated in data-dependent mode with survey scans acquired at a resolution 
of 75,000 at m/z 200 (transient time 256 ms). Up to 10 of the most abundant isotope patterns 
with charge +2 or higher from the survey scan were selected with an isolation window of 3.0 
m/z and fragmented by HCD with normalized collision energies of 25. The maximum ion 
injection times for the survey scan and the MS/MS scans (acquired with a resolution of 17 
500 at m/z 200) were 20 and 120 ms, respectively. The ion target value for MS was set to 
106 and for MS/MS to 105, and the intensity threshold was set to 8.3 × 102. 
Data searching and analysis. The data were processed with MaxQuant version 1.3.0.5, 
and the peptides were identified from the MS/MS spectra searched against TriTrypDB-6.0 L. 
donovani LdBPK282A1 database using the Andromeda search engine. The protein HASPB 
was not present in this database and so the Uniprot sequence (O77300_LEIDO) was 
appended to the FASTA file. Cysteine carbamidomethylation was used as a fixed 
modification, and methionine oxidation and N-terminal acetylation as variable modifications. 
The false discovery rate was set to 0.01 for peptides, proteins and sites. Other parameters 
were used as pre-set in the software. “Unique and razor peptides” mode was selected to 
allow for protein grouping; this calculates ratios from unique and razor peptides (razor 
peptides are uniquely assigned to protein groups and not to individual proteins). Data were 
elaborated using Microsoft Office Excel 2007 and Perseus versions 1.4.0.20 and 1.5.0.31. 
Label free quantification (LFQ) experiments in MaxQuant were performed using the built-in 
label-free quantification algorithm (Cox et al., 2014). 
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Modified peptide identification. MS data were processed with PEAKS7 suite (Zhang et al., 
2012). The data were searched against a reference L. donovani database from Uniprot 
(27/11/2014). Trypsin (specific, up to three missed cleavages allowed) was selected for 
database searches, and no enzyme was chosen for de novo searches. The maximal mass 
error was set to 5 ppm for precursor ions and 0.01 Da for product ions. 
Carbamidomethylation was selected as a fixed modification, and methionine oxidation as 
well as the lipid-derived adduct (+534.3278 Da) to any amino acid at peptide N-terminus 
were set as variable modifications. The maximal number of modifications per peptide was 
set as five. The false discovery rate was set to 0.01 for peptides, and b1 ions were required 
for N-terminally modified peptides. Within PEAKS, a module called SPIDER searches for 
point mutations to further enhance the discovery (Ma and Johnson, 2011). All peptides 
reported are N-terminal peptides unique for the protein that they were assign to by the 
software. 
Data processing: YnMyr tagged proteins in amastigotes and promastigotes. 
Amastigote experiments: four replicates were performed independently, starting from the 
same metabolically labelled lysates (Myr and YnMyr samples) through the sample 
preparation steps and LC-MS/MS analysis. The replicates were grouped together (groups: 
Myr, YnMyr). YnMyr protein group was filtered to require three valid values across the four 
replicates. Label free intensities were logarithmized (base 2) and empty values were imputed 
with random numbers from a normal distribution, whose mean and standard deviation were 
chosen to simulate low abundance values close to noise level (impute criteria: width 0.1 and 
down shift 1.8). A modified t-test with permutation based FDR statistics was applied (250 
permutations; FDR = 0.05; S0 = 1). Imputing missing values enables assessment of whether 
a protein is enriched above background noise levels and facilitates statistical analyses, but is 
likely to generate false negatives where a genuine hit protein is of low abundance in the 
sample. To explore this possibility empty values were reinstated and data analysed to 
assess whether a protein was absent from the control but still met the other criteria (present 
in three out of four amastigote replicates). Proteins absent from the control sample but not 
reaching significance were designated ‘low abundance hits’. Proteins reaching significance 
in the t-test and absent from the control sample were designated as ‘high confidence hits’. 
Promastigote experiments: three replicates were performed independently, starting from the 
same metabolically labelled lysates (Myr and YnMyr samples) through the sample 
preparation steps and LC-MS/MS analysis. Data were analysed as described above with 3 
valid values per group required, imputation (width 0.1 and down shift 1.8), and t-test (250 
permutations; FDR = 0.01; S0 = 1). 
For the comparison of amastigotes and promastigotes, data were filtered for at least three 
valid values in at least one group (groups: Am_Myr, Am_YnMyr, Pro_Myr, Pro_YnMyr). 
Missing values were imputed as above and proteins cross-referenced with the independent 
analyses described above that defined t-test significant, low abundance and high confidence 
hits. Datasets were also compared by a two sample t-test: YnMyr intensities of hits (defined 
as proteins that were either t-test significant or classed as low abundance hits in the 
independent analyses) were compared by permutation-corrected t-test (250 permutations; 
FDR 0.05, S0 2) after imputation of missing values (width 0.1, downshift 2.5). These 
parameters were chosen so that proteins only found in one of the two datasets were 
significant in the t-test. 
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Data processing: YnMyr tagging in the presence of NMT inhibitors (amastigotes). The 
experiment design was as follows: independent biological experiments were carried out 
where amastigotes were incubated with YnMyr, YnMyr + 0.2 μM 2, YnMyr + 0.2 μM 1, or 
YnMyr + 7 μM 1. A Myr control was included in one of these experiments. For proteomics 
analysis, all samples were prepared and processed in duplicate (technical replicates: A&B; 
C&D). The ‘Match between runs’ option (time window 2 minutes) in Maxquant was enabled 
during the searches. Data were grouped, filtered to retain only those proteins present in both 
biological experiments, and non-specific binders removed (leaving 346 proteins); for the 
latter step, enrichment over control (‘Myr LFQ ratio’), calculated by taking the mean of the 
YnMyr intensities and dividing by the mean of the Myr intensities, was required to be ≥2. 
Missing values were imputed from a normal distribution (width 0.1 and down shift 1.8) and 
modified two sample t-tests with permutation based FDR statistics were applied to assess 
differences between groups (250 permutations; FDR = 0.001; S0 = 1, unless otherwise 
indicated). An ANOVA (Benjamini Hochberg correction, FDR=0.001) was also applied to 
LFQ intensities to compare across all datasets. 
Bioinformatics 
Modification of proteins was predicted using the following bioinformatic tools: 
For N-myristoylation: the Myr predictor (MPred) (Maurer-Stroh et al., 2002) and the 
Myristoylator (Myr) (Bologna et al., 2004). 
For S-palmitoylation CSS-Palm 3.0 (Ren et al., 2008; Zhou et al., 2006). 
For GPI-anchor modification PredGPI (Pierleoni et al., 2008), GPI-SOM (Fankhauser and 
Maser, 2005) and FragAnchor (Poisson et al., 2007). 
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